Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Conditions
Interventions
Intervention1: cadamba drug therapy: 1st 3 days 6 doses in every 2 hours
QID 3 days
then TDS for weeks
potency 200
Sponsors
Dr Priti katre
Eligibility
Inclusion criteria
Inclusion criteria: 1 COVID affected individual (serologically positive) symptomatic, mild hospitalized 2 asymptomatic (serologically positive)
Exclusion criteria
Exclusion criteria: 1.Malabsorption or inadequate oral intake 2.unexplained, chronic diarrhea, defined as more than 3 loose stool per day persisting for 2 weeks or more within the month prior to study entry. 3. Active malignancy or anticipated need for chemotherapy during the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| with refrance to time scale T1-T4 -- from 5-7 weeks we expect complete recovery of patient who presented with initial symptoms. 1 patient should be asymptomatic with gental recovery (with serologically negative blood test) within 7-14 days after administration of 1st dose of medicine. 2 asymptomatic patient (serologically positive) will remain asymptomatic and should be serologically negative after 7-14 days of treatment.Timepoint: with refrance to time scale T1-T4 -- from 5-8 weeks we expect complete recovery of patient who presented with initial symptoms. | — |
Secondary
| Measure | Time frame |
|---|---|
| with refrance to time scale T1-T5 if patient have late symptoms with initial pathological changes in vital organs we expect recovery by day 14 1 we can conclude after the study is complete. Timepoint: (T1 to T5) T1- presentation before medicine intake. T2- observation for 1-3 days after drug intake. T3- 3 to 7days gradual disappearance of initial symptoms. T4- after 7 days recovery expected. T5- If associated with other secondary complaints expected recovery is by 7-14 days. | — |
Countries
India
Contacts
Public ContactPrashant katre
Homoeo clinic
Outcome results
None listed